Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III confirmatory study of KPS-0373 in spinocerebellar degeneration
jRCT2011250017Phase 3Active, not recruiting
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
- Start
- Jul 2025
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3 trial of rovatirelin in spinocerebellar ataxia (SCA) (2 arms), sponsored by Kissei Pharmaceutical Co., Ltd. Primary endpoint: Change from baseline in total SARA score at Week 24. Started Jul 2025; status: active, not recruiting.
02
Drugs
rovatirelin
03
Conditions
spinocerebellar ataxia (SCA)
Beyond the preview
Go deeper on jRCT2011250017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011250017.